The Hypereosinophilic Syndrome Revisited
- 1 February 2003
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 54 (1) , 169-184
- https://doi.org/10.1146/annurev.med.54.101601.152431
Abstract
Clinical and biological features of patients with the idiopathic hypereosinophilic syndrome (HES) are heterogeneous. Recent evidence suggests at least two distinct underlying hematological disorders involving myeloid and lymphoid cells, respectively. We therefore suggest that the term idiopathic should be abandoned in the classification of HES. This review defines the “myeloproliferative” and “lymphocytic” variants of the HES and addresses the management of each variant, focusing on diagnosis and treatment of the newly identified lymphocytic variant.Keywords
This publication has 34 references indexed in Scilit:
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002
- Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activityJournal of Allergy and Clinical Immunology, 2001
- The Hypereosinophilic Syndrome Associated with CD4+CD3″ Helper Type 2 (Th2) LymphocytesLeukemia & Lymphoma, 2001
- HypereosinophiliaCurrent Opinion in Hematology, 2000
- Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic EosinophiliaNew England Journal of Medicine, 1999
- FludarabineDrugs, 1997
- TH1 and TH2 in Human DiseasesClinical Immunology and Immunopathology, 1996
- Eosinophilia associated with proliferation of CD3 + 4 − 8 − αβ + T cells with chromosome 16 anomaliesBritish Journal of Haematology, 1996
- Eosinophils in the 1990s: New perspectives on their role in health and diseasePostgraduate Medical Journal, 1994
- THE HYPEREOSINOPHILIC SYNDROMEMedicine, 1975